This month’s Cabot Small-Cap Confidential investment candidate is Sangamo Biosciences (SGMO), a clinical-stage biopharmaceutical company that focuses on the development of zinc finger DNA-binding proteins that are showing great promise in gene modification for treatment of HIV/AIDS, Alzheimer’s, hemophilia, Huntington’s disease and other widespread diseases.
